West Pharmaceutical Services (WST) Non-Current Deffered Revenue (2019 - 2026)

West Pharmaceutical Services has disclosed Non-Current Deffered Revenue across 8 years of filings, most recently posting $11.8 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $11.8 million, up 3.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.8 million (up 3.51% YoY), and the FY2025 annual result was $13.5 million, down 12.34% from the prior year.
• Non-Current Deffered Revenue came in at $11.8 million for Q1 2026 at West Pharmaceutical Services, down from $13.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $26.3 million in Q1 2022 to a low of $11.4 million in Q1 2025.
• The 5-year median for Non-Current Deffered Revenue is $17.9 million (2023), against an average of $17.0 million.
• Across the five-year window, Non-Current Deffered Revenue advanced 16.89% in 2022 and slumped 38.71% in 2025, its largest moves.
• West Pharmaceutical Services' Non-Current Deffered Revenue stood at $19.1 million in 2022, then decreased by 2.62% to $18.6 million in 2023, then retreated by 17.2% to $15.4 million in 2024, then decreased by 12.34% to $13.5 million in 2025, then decreased by 12.59% to $11.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $11.8 million (Q1 2026), $13.5 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.